ALLO News and Press, Allogene Therapeutics Inc. From 04/21/21

RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma Patients UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating...

The FDA has cleared an Investigational New Drug ((IND)) application of Allogene Therapeutics (ALLO) to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma.ALLO-605 is part of the company’s multi-faceted strategy to develop an allogeneic CAR T thera...

TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T™ Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene’s Three Strategies to Target...

Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...

Allogene Therapeutics (ALLO) and SpringWorks Therapeutics (SWTX) announce that the first patient has been dosed in a Phase 1 trial evaluating the company's investigational anti-B-cell maturation antigen ((BCMA)) AlloCAR T therapy, in combination with nirogacestat in patients with relapse...

SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and Spri...

Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells New TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making Cytokine Activation Dependent Upon the Tumor Microenvironment and Overcoming...

Allogene is a world leader in allogeneic CAR-T. Since my last article, the stock has seen some appreciation. ALLO is shaping up to be a good investment. For further details see: Allogene: World Leader In Allogeneic CAR-T

Allogene Therapeutics, Inc. (ALLO) Q4 2020 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President-Research and Development and Chie...

Presented Initial Phase 1 UNIVERSAL Trial Data on ALLO-715 at The American Society of Hematology (ASH) Meeting Providing First Proof-of-Concept for an AlloCAR T™ Therapy in Relapsed/Refractory Multiple Myeloma Updated ALLO-501 and Initial ALLO-501A AlloCAR T Data in Non-Hodgkin...